is mounjaro tirzepatide second obesity drug to be approved for use in England | Obesity Mounjaro (Tirzepatide): Raising the Bar

This may relate to tirzepatide's potentially better muscle preservation and its different impact on glucose metabolism through dual receptor activation

for semaglutide, liraglutide and dulaglutide, no dose adjustment is generally required, but monitor in severe renal impairment, especially with gastrointestinal losses Pregnancy and breastfeeding: GLP-1 therapies are not recommended during pregnancy

Market Growth Prospects: Emerging markets, particularly in Asia and Latin America, present significant growth opportunities for S-acetyl-L-glutathione

Vegetarians and vegans have about 50% less carnosine in their muscles compared to omnivores (28)

The request for a standalone MDL follows studies from Harvard and JAMA Ophthalmology suggesting that GLP-1 drugs may increase the risk of NAION up to sevenfold